Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/29/2025

HIV Immunology

Mechanism of Infection and Viral Replication

  • The HIV virus infects primarily cells that express the CD4 receptor, including CD4+ T lymphocytes, macrophages, and dendritic cells, leading to immunodeficiency and increased susceptibility to opportunistic infections and neoplasias 1
  • The viral replication cycle begins with the binding of the gp120 glycoprotein to the CD4 receptor and a co-receptor (mainly CCR5 or CXCR4) on the cell surface, followed by the release of viral genetic material into the cytoplasm and conversion to DNA by reverse transcriptase 2
  • The viral DNA is then integrated into the host cell genome by the integrase enzyme, forming the provirus, which can remain dormant or be transcribed to produce new viral particles 1
  • The replication of the virus occurs when the infected cell is activated, leading to the production of new viral particles that can infect other cells 2

Impact on Immune Response

  • The primary characteristic of HIV infection is the progressive depletion of CD4+ T lymphocytes, which are essential for coordinating the immune response, leading to immunodeficiency and increased susceptibility to opportunistic infections and neoplasias 3
  • Uncontrolled viremia causes immune activation and chronic inflammation, increasing the risk of long-term complications such as coronary artery disease, stroke, neurocognitive impairment, neoplasias, and osteoporosis 2
  • HIV viremia is an independent risk factor for death, regardless of CD4 cell count 2

Disease Progression

  • Without treatment, HIV infection progresses through different clinical and immunological stages, including acute infection, chronic phase, and advanced phase, characterized by CD4 counts below 200 cells/mm³ and increased risk of opportunistic infections 4
  • The normal CD4 count varies with age, with higher counts in infants and children, and decreases gradually to adult values by around 5 years of age 5

Immunological Monitoring

  • CD4 cell count and viral load are the primary laboratory parameters for monitoring disease progression and response to treatment, with recommendations for monitoring CD4 count every 3-4 months to assess the need for antiretroviral therapy (ART) or treatment efficacy 6
  • For patients on suppressive ART regimens with significantly increased CD4 counts above the threshold for opportunistic infections, monitoring can be performed every 6-12 months 6

Impact of Treatment on Immunology

  • Antiretroviral therapy (ART) suppresses viral replication, allowing for partial reconstitution of the immune system, and is associated with improved immunological recovery and reduced risk of AIDS-related and non-AIDS-related complications 2
  • Early initiation of ART is associated with better immunological recovery and reduced risk of complications, and can lead to the elimination of unnecessary therapies, such as prophylaxis for opportunistic infections 1

Special Considerations in Specific Populations

Children

  • Infants infected with HIV should initiate ART in the first year of life, regardless of CD4 count, viral load, or clinical status, due to rapid disease progression in this age group 4
  • Normal CD4 counts in children are higher than in adults and decrease gradually to adult values by around 6 years of age, with percentage of CD4 being a better marker for identifying disease progression in young children 5

Pregnant Women

  • Pregnant women should be treated for HIV infection, regardless of immunological or virological status, to prevent mother-to-child transmission, with a transmission rate of <1% in women who achieve undetectable viral load during treatment 7